Yi Li

Yi Li is an experienced regulatory affairs professional with a strong background in the pharmaceutical industry. Currently serving as the Director of Regulatory Affairs and China RA Head at Lundbeck since April 2022, Yi Li previously held significant roles at Novartis Oncology, including RA Director and Acting China Program Head, from March 2016 to April 2022. Earlier experience includes serving as Associate RA Director at Merck Group, TA Head at Sanofi, and Regulatory Affairs Specialist at Servier. Yi Li began a professional career at Peking Union Medical College as a research associate focused on drug development and registration. Yi Li holds a Master’s degree in Pharmaceutical Analysis from Peking Union Medical College and a Bachelor’s degree in Pharmaceutical Sciences from Sichuan University.